Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575347 | 1.00 | NFE2L2 (0.50) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| Acetic Acid SCHEMBL27299032 | 0.86 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL37099 | 0.83 | — | — | |
| SCHEMBL182365 | 0.83 | — | — | |
| SCHEMBL2179903 | 0.83 | — | — | |
| SCHEMBL30753633 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL27497466 | 0.81 | — | — | |
| Methyl Alcohol SCHEMBL5706210 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL27905193 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL27755931 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371674-B2 | Enone reductases | CODEXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-9388438-B2 | Enone reductases | CODEXIS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150315613-A1 | ENONE REDUCTASES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-11-05 | — | — | US | disclosed |
| EP-2382308-A2 | ENONE REDUCTASES | Codexis, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371674-B2 | Enone reductases | ENO1, DCXR, RRM2B | NFE2L2 1736/4885HCAR2 4673/4885KEAP1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.